BioCentury | Jun 5, 2019

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific...
BioCentury | May 30, 2019
Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
BioCentury | Mar 19, 2019
Preclinical News

Merrimack develops bispecific against c-MET oncogene

Merrimack has overcome hurdles to antibody targeting of c-MET with a bispecific that increases avidity by anchoring to a tumor surface protein. Marketed small molecules inhibiting c-MET, which drives tumor formation, metastasis and resistance to...
BioCentury | Jun 9, 2017
Company News

WuXi Biologics performing CMC work for EpimAb's EMB-01

WuXi Biologics Inc. (HKSE:2269) agreed to provide chemistry, manufacturing and control (CMC) services for the development of preclinical oncology candidate EMB-01 from EpimAb Biotherapeutics Inc. (Shanghai, China). WuXi is responsible for the program’s CMC portion...
BioCentury | Apr 29, 2017

Building bispecifics

Encouraging preclinical data and a broadly applicable bispecifics platform helped Shanghai-based EpimAb Biotherapeutics Inc. attract $25 million in series A funding from a syndicate of Chinese, U.S. and U.K. investors. "Most biologics companies in China...
Items per page:
1 - 5 of 5